These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 34662688)

  • 1. Plasma mid-regional pro-atrial natriuretic peptide predicts cardiovascular events in patients with type 2 diabetes independently of subclinical organ damage.
    Gauffin E; Chisalita SI; Engvall J; Nyström FH; Östgren CJ
    Diabetes Res Clin Pract; 2021 Dec; 182():109095. PubMed ID: 34662688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MR-proANP improves prediction of mortality and cardiovascular events in patients with STEMI.
    Lindberg S; Jensen JS; Pedersen SH; Galatius S; Goetze JP; Mogelvang R
    Eur J Prev Cardiol; 2015 Jun; 22(6):693-700. PubMed ID: 24906365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma MR-proANP levels are associated with carotid intima-media thickness in the general community: the KORA F4 study.
    Then C; Kowall B; Lechner A; Meisinger C; Heier M; Koenig W; Peters A; Thiery J; Rathmann W; Seissler J
    Atherosclerosis; 2013 Oct; 230(2):235-41. PubMed ID: 24075750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased plasma concentrations of midregional proatrial natriuretic Peptide is associated with risk of cardiorenal dysfunction in type 1 diabetes.
    Theilade S; Hansen TW; Goetze JP; Rossing P
    Am J Hypertens; 2015 Jun; 28(6):772-9. PubMed ID: 25468806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toe brachial index predicts major acute cardiovascular events in patients with type 2 diabetes independently of arterial stiffness.
    Chisalita SI; Wijkman M; Davidson LT; Spångeus A; Nyström F; Östgren CJ
    Diabetes Res Clin Pract; 2020 Mar; 161():108040. PubMed ID: 32006647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MR-proANP and incident cardiovascular disease in patients with type 2 diabetes with and without heart failure with preserved ejection fraction.
    Jensen J; Schou M; Kistorp C; Faber J; Hansen TW; Jensen MT; Andersen HU; Rossing P; Vilsbøll T; Jørgensen PG
    Cardiovasc Diabetol; 2020 Oct; 19(1):180. PubMed ID: 33066783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating TNFrII levels predict incidence of ischemic heart disease and total mortality, independently of intima media thickness and pulse wave velocity in male with type 2 diabetes.
    Johansson MA; Vavruch C; Östgren CJ; Nystrom FH
    Heart Vessels; 2021 Oct; 36(10):1591-1596. PubMed ID: 33871700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The midregional fragment of pro-A-type natriuretic peptide, blood pressure, and mortality in a prospective cohort study of patients with type 2 diabetes (ZODIAC-25).
    van Hateren KJ; Landman GW; Kleefstra N; Groenier KH; Struck J; Navis GJ; Bakker SJ; Houweling ST; van der Meer K; Bilo HJ
    Diabetes Care; 2013 May; 36(5):1347-52. PubMed ID: 23230100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Midregional pro atrial natriuretic peptide: a novel important biomarker for noise annoyance-induced cardiovascular morbidity and mortality?
    Hahad O; Wild PS; Prochaska JH; Schulz A; Lackner KJ; Pfeiffer N; Schmidtmann I; Michal M; Beutel M; Daiber A; Münzel T
    Clin Res Cardiol; 2021 Jan; 110(1):29-39. PubMed ID: 32306084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of midregional pro-A-type natriuretic peptide and the N-terminal pro-B-type natriuretic peptide for predicting mortality and cardiovascular events.
    van Hateren KJ; Alkhalaf A; Kleefstra N; Groenier KH; de Jong PE; de Zeeuw D; Gans RO; Struck J; Bilo HJ; Gansevoort RT; Bakker SJ
    Clin Chem; 2012 Jan; 58(1):293-7. PubMed ID: 21948291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aortic pulse wave velocity predicts incident cardiovascular events in patients with type 2 diabetes treated in primary care.
    Wijkman M; Länne T; Östgren CJ; Nystrom FH
    J Diabetes Complications; 2016; 30(7):1223-8. PubMed ID: 27400814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Central blood pressure and pulse wave velocity: relationship to target organ damage and cardiovascular morbidity-mortality in diabetic patients or metabolic syndrome. An observational prospective study. LOD-DIABETES study protocol.
    Gómez-Marcos MA; Recio-Rodríguez JI; Rodríguez-Sánchez E; Castaño-Sánchez Y; de Cabo-Laso A; Sánchez-Salgado B; Rodríguez-Martín C; Castaño-Sánchez C; Gómez-Sánchez L; García-Ortiz L
    BMC Public Health; 2010 Mar; 10():143. PubMed ID: 20298558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations of cardiac stress biomarkers with incident type 2 diabetes and changes in glucose metabolism: KORA F4/FF4 study.
    Sujana C; Seissler J; Jordan J; Rathmann W; Koenig W; Roden M; Mansmann U; Herder C; Peters A; Thorand B; Then C
    Cardiovasc Diabetol; 2020 Oct; 19(1):178. PubMed ID: 33066780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Natriuretic Peptides as Risk Markers for All-Cause Mortality and Cardiovascular and Renal Complications in Individuals With Type 1 Diabetes.
    Tofte N; Theilade S; Winther SA; Birkelund S; Goetze JP; Hansen TW; Rossing P
    Diabetes Care; 2021 Feb; 44(2):595-603. PubMed ID: 33323477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality.
    Pavo N; Raderer M; Hülsmann M; Neuhold S; Adlbrecht C; Strunk G; Goliasch G; Gisslinger H; Steger GG; Hejna M; Köstler W; Zöchbauer-Müller S; Marosi C; Kornek G; Auerbach L; Schneider S; Parschalk B; Scheithauer W; Pirker R; Drach J; Zielinski C; Pacher R
    Heart; 2015 Dec; 101(23):1874-80. PubMed ID: 26416836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of multiple emerging biomarkers in cardiovascular risk prediction in patients with stable cardiovascular disease.
    Ahluwalia N; Blacher J; Szabo de Edelenyi F; Faure P; Julia C; Hercberg S; Galan P
    Atherosclerosis; 2013 Jun; 228(2):478-84. PubMed ID: 23582589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct comparison of mid-regional pro-atrial natriuretic peptide with N-terminal pro B-type natriuretic peptide in the diagnosis of patients with atrial fibrillation and dyspnoea.
    Eckstein J; Potocki M; Murray K; Breidthardt T; Ziller R; Mosimann T; Klima T; Hoeller R; Moehring B; Sou SM; Rubini Gimenez M; Morgenthaler NG; Mueller C
    Heart; 2012 Oct; 98(20):1518-22. PubMed ID: 22865868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mid-regional pro-atrial natriuretic peptide levels in the elderly: clinical and prognostic implications, and comparison to B-type natriuretic peptides.
    Eggers KM; Venge P; Lind L
    Clin Chim Acta; 2013 Apr; 419():62-6. PubMed ID: 23415698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelial markers may link kidney function to cardiovascular events in type 2 diabetes.
    Maier C; Clodi M; Neuhold S; Resl M; Elhenicky M; Prager R; Moertl D; Strunk G; Luger A; Struck J; Pacher R; Hülsmann M
    Diabetes Care; 2009 Oct; 32(10):1890-5. PubMed ID: 19564455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The association of mid-regional pro-adrenomedullin and mid-regional pro-atrial natriuretic peptide with mortality in an incident dialysis cohort.
    Gouya G; Sturm G; Lamina C; Zitt E; Freistätter O; Struck J; Wolzt M; Knoll F; Lins F; Lhotta K; Neyer U; Kronenberg F
    PLoS One; 2011 Mar; 6(3):e17803. PubMed ID: 21408188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.